Back to Results
First PageMeta Content
Gadodiamide / Nephrogenic systemic fibrosis / Magnetic resonance imaging / Radiocontrast agent / Ketorolac / Lorazepam / MRI contrast agent / Cardiac MRI perfusion / Chemistry / Matter / Gadolinium


Document Date: 2012-01-25 10:22:42

Open Document

File Size: 350,83 KB

Share Result on Facebook

City

Gadolinium / /

Company

Bayer HealthCare Pharmaceuticals Inc. / /

Event

FDA Phase / Product Issues / /

IndustryTerm

diagnostic magnetic resonance imaging / physiological saline solution / yellow solution / contrast media / rubber stopper / chemical / imaging / /

MedicalCondition

Nephrogenic Systemic Fibrosis Gadolinium-based contrast agents / loss of consciousness / chronic / severe kidney disease / local irritation / hypertension / severe kidney disease / bronchospasm / bronchial asthma / chest pain / laryngeal edema / disease / flushing / headache / kidney disease / moderate irritation / dysgeusia / shock / Carcinogenesis / Acute kidney injury / dysfunction / Chronic / convulsion / nausea / diabetes / allergic disorders / hyperhidrosis / chronic hypertension / conjunctivitis / injury / diabetes mellitus / urticaria / angioedema / tachycardia / Hypersensitivity / anaphylactic reactions / inflammatory cells / infection / Cardiac arrest / cough / Anaphylactoid/anaphylactic reactions / Pruritus / NEPHROGENIC SYSTEMIC FIBROSIS / fibrosis / hypotension / /

MedicalTreatment

catheter / resuscitation / hemodialysis / cannula / drug therapy / surgery / dialysis / /

Organization

Before Gadavist administration / National Science Foundation / DOSAGE AND ADMINISTRATION / FDA / Gadavist administration / /

/

Position

General / /

Product

Gadavist injection / VOLUME OF GADAVIST INJECTION / Palm Pre Plus Smartphone / elimination / L / Gadavist / /

Technology

Pharmacokinetics / MRI system / magnetic resonance imaging / Pharmacodynamics / MRI / dialysis / /

URL

www.fda.gov/medwatch / /

SocialTag